BioXcel Therapeutics Inc (FRA:BX2)
€ 1.892 0.006 (0.32%) Market Cap: 72.49 Mil Enterprise Value: 98.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 21/100

BioXcel Therapeutics Inc at UBS Global Healthcare Conference (Virtual) Transcript

May 18, 2020 / 08:40PM GMT
Release Date Price: €43.2 (-4.42%)
Pehlaaj Bajwa
UBS Investment Bank - Associate Director

Good afternoon and thank you for attending the 2020 Virtual UBS Global Healthcare Conference. My name is Pehlaaj Bajwa, and I will be your host for this session. A Q&A session will follow immediately after the presentation. To submit a question, please type your question in the Q&A prompt on the presentation screen. Note, questions will be anonymous.

I'm pleased to introduce our presenter, Dr. Vimal Mehta, Chief Executive Officer of BioXcel Therapeutics. Vimal, please go ahead.

Vimal D. Mehta
BioXcel Therapeutics, Inc. - Founder, CEO, President, Secretary & Director

Thanks, Pehlaaj. Good afternoon. I'm Dr. Vimal Mehta, Chief Executive Officer of BioXcel Therapeutics, a clinical-stage company utilizing artificial intelligence approaches to identify and advance novel opportunities in neuroscience and immuno-oncology. I want to thank Pehlaaj and the UBS team for organizing this conversation and providing us with another opportunity to stay in communication with our investors during this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot